International Journal of Clinical Oncology最新文献

{"title":"Comment on: significance of preoperative mean corpuscular volume in patients with stage II/III colorectal cancer and anemia.","authors":"Min Zou, Yansheng Zhang, Feng Gao, Zengqiang Yang","doi":"10.1007/s10147-025-02882-3","DOIUrl":"https://doi.org/10.1007/s10147-025-02882-3","url":null,"abstract":"","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145102766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; nivolumab plus ipilimumab for colorectal cancer, trastuzumab deruxtecan for breast cancer, and acalabrutinib for mantle cell lymphoma.","authors":"Noriomi Matsumura, Masaki Mandai","doi":"10.1007/s10147-025-02879-y","DOIUrl":"https://doi.org/10.1007/s10147-025-02879-y","url":null,"abstract":"","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-resistance among novel androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer.","authors":"Takuya Oishi, Naoki Fujita, Yohei Kawashima, Masanao Shinohara, Ryuji Tabata, Fumiya Yoneyama, Ryuma Tanaka, Hikari Miura, Kyo Togashi, Kazutaka Okita, Hirotaka Horiguchi, Toshikazu Tanaka, Daisuke Noro, Yuichiro Suzuki, Satoshi Sato, Chikara Ohyama, Shingo Hatakeyama","doi":"10.1007/s10147-025-02881-4","DOIUrl":"https://doi.org/10.1007/s10147-025-02881-4","url":null,"abstract":"<p><strong>Background: </strong>Sequential therapy with different novel androgen receptor signaling inhibitors (ARSIs) is a possible treatment option for patients who have increased prostate-specific antigen (PSA) levels. The aim of the present study was to investigate cross-resistance among ARSIs and its predictors in non-metastatic castration-resistant prostate cancer (nmCRPC).</p><p><strong>Methods: </strong>In this multicenter retrospective study, we evaluated 75 patients with nmCRPC who had progressed after treatment with one ARSI and were subsequently treated with a second ARSI. The primary endpoint was cross-resistance among ARSIs, which was identified by comparing PSA responses to treatment with first and second ARSIs. The secondary endpoints were changes in PSA doubling time (PSADT) from diagnosis of nmCRPC to initiation of treatment with a second ARSI and predictors of PSA non-responsiveness to treatment with that second ARSI.</p><p><strong>Results: </strong>The rates of any PSA response, PSA decline ≥ 50%, and PSA decline ≥ 90% to treatment with a second ARSI were significantly lower than those to the first ARSI administered (45% vs. 88%, P < 0.001; 9.3% vs. 71%, P < 0.001; 2.7% vs. 33%, P < 0.001; respectively). The PSADT shortened to some degree in 31 patients (41%). According to multivariable analysis, only PSADT before initiation of treatment with a second ARSI was significantly associated with no PSA response to treatment with that second ARSI.</p><p><strong>Conclusions: </strong>We identified significant cross-resistance among ARSIs in patients with nmCRPC. The PSADT before initiation of treatment with a second ARSI may be useful for predicting the efficacy of treatment with a second ARSI.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145064605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of mycophenolate mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): a multicenter, phase II clinical trial.","authors":"Nut Koonrungsesomboon, Pimpisa Teeyakasem, Nahathai Dukaew, Nutnicha Sirikaew, Patcharawadee Thongkumkoon, Petlada Yongpitakwattana, Viraporn Thepbundit, Parunya Chaiyawat, Jeerawan Klangjorhor, Chotiwit Sakuludomkan, Chaiyut Charoentum, Busyamas Chewaskuyong, Lalita Sathitsamitphong, Piya Kiatisevi, Patrapim Sunpaweravong, Chirawadee Sathitruangsak, Dumnoensun Pruksakorn","doi":"10.1007/s10147-025-02877-0","DOIUrl":"https://doi.org/10.1007/s10147-025-02877-0","url":null,"abstract":"<p><strong>Background: </strong>Osteosarcoma is a prevalent and aggressive bone malignancy primarily affecting young adults. Despite advances in standard treatment, the 5-year survival rate remains low, highlighting the need for new chemotherapy options. Mycophenolate mofetil, an immunosuppressant used post-transplant, has shown promising preclinical anticancer effects in osteosarcoma, warranting further investigation for potential repurpose in humans.</p><p><strong>Methods: </strong>We conducted this proof-of-concept phase II clinical trial to assess the efficacy and safety of mycophenolate mofetil in high-grade locally advanced or metastatic osteosarcoma. Patients received 3-5 g/day mycophenolate mofetil for four 28-day cycles or until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) at 16 weeks. Secondary endpoints included overall survival (OS), overall response rate, safety, pharmacokinetics, pain score, and quality of life.</p><p><strong>Results: </strong>Fifteen patients were enrolled. Due to intolerable toxicity at higher doses, most patients received 3 g/day of mycophenolate mofetil. At 16 weeks, the PFS rate was 40%, with only one patient (6.7%) achieving stable disease. Median PFS and OS were 70 and 301 days, respectively. The most common grade 3-4 adverse events were anemia and fatigue, each occurring in 20% of patients. Pharmacokinetic analysis revealed high interindividual variability.</p><p><strong>Conclusion: </strong>Although mycophenolate mofetil at 3 g/day was well tolerated, it did not meet expectations for anticancer efficacy in patients with high-grade locally advanced or metastatic osteosarcoma. This study should be considered a negative trial. Further research is needed to explore the therapeutic role of mycophenolate mofetil through alternative strategies or identify more effective interventions for osteosarcoma.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Socioeconomic disparities in colorectal cancer oncologic emergencies: a nationwide multilevel analysis in Japan.","authors":"Mariko Hanafusa, Nobutoshi Nawa, Masato Ota, Tomoki Nakaya, Yasuhito Fujisaka, Kiyohide Fushimi, Takeo Fujiwara, Yuri Ito","doi":"10.1007/s10147-025-02876-1","DOIUrl":"https://doi.org/10.1007/s10147-025-02876-1","url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) oncologic emergency presentations are associated with poor prognosis and place a significant burden on health care resources. While tumor and biological patient factors have been reported as risk factors, social determinants have not been thoroughly examined. This study aimed to examine the frequency of CRC oncologic emergencies and its association with neighborhood deprivation.</p><p><strong>Methods: </strong>We used the Diagnosis Procedure Combination (DPC) database, a nationwide administrative dataset in Japan, for patients diagnosed with CRC receiving specific treatment for the 2014-2019 fiscal years. Neighborhood deprivation was assessed by linking patient residential postcodes and area deprivation index (ADI). We used a multilevel logistic regression model to compare the likelihood of oncologic emergencies across different degrees of ADI and examined effect modification by sex through age-stratified analysis to consider differences in social structures.</p><p><strong>Results: </strong>Of 488,841 eligible CRC patients, 56,311 (11.5%) had experienced an oncologic emergency. We identified a disparity: the higher the degree of ADI, the greater the likelihood of oncologic emergencies (odds ratio for most vs. least deprived area 1.19; 95% confidence interval 1.15-1.23). This disparity was more pronounced in males than in females, but was observed only among middle-aged males, among whom regular employment was most common.</p><p><strong>Conclusion: </strong>The likelihood of oncologic emergencies was higher in the neighborhoods with higher deprivation levels. The magnitude of this disparity differed by sex and was particularly pronounced among those of working age, underscoring the need to further explore how socioeconomic factors-such as access to workplace cancer screening-shape these differences.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145053036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal nationwide analysis of uveal melanoma in the United States1995-2018.","authors":"Ahmad Samir Alfaar, Mohamed H Abdel-Rahman, Moataz Hamed Osman","doi":"10.1007/s10147-025-02870-7","DOIUrl":"https://doi.org/10.1007/s10147-025-02870-7","url":null,"abstract":"<p><strong>Purpose: </strong>Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, yet comprehensive nationwide epidemiologic data remain limited. This study aimed to provide an updated analysis of UM incidence, survival, and disparities in the United States (US) using near-complete population coverage.</p><p><strong>Methods: </strong>We analyzed data from the North American Association of Central Cancer Registries (NAACCR) and US Cancer Statistics (USCS) program between 1995 and 2018, covering 98-100% of the US population. Age-adjusted incidence rates (AAIRs) and relative survival were calculated using SEER*Stat and Joinpoint regression.</p><p><strong>Results: </strong>A total of 37,917 UM cases were identified, with an overall AAIR of 5.54 per million (95% CI: 5.48-5.59), showing a stable but slightly increasing trend (AAPC = 0.06). Incidence was highest in non-Hispanic whites (6.87 ppm), men (6.25 ppm), and those aged 75-79 years. Geographic variation was notable, with peak incidence in Oregon and Iowa. Most tumors (81.3%) were localized at diagnosis, and 27.4% of patients had another primary malignancy. 5- and 10-year relative survival rates were 83.3% and 73.9%, respectively, with worse outcomes in metastatic disease. A shift toward radiotherapy, especially brachytherapy, was observed, although survival gains remained limited.</p><p><strong>Conclusions: </strong>This nationwide study refines US UM incidence estimates and highlights persistent disparities by sex, race, age, and geography. The high prevalence of secondary malignancies underscores the need for genetic counseling and extended surveillance. Despite advances in imaging, local therapies (e.g., brachytherapy, proton therapy), and emerging systemic approaches including immunotherapy, survival improvements in advanced UM remain limited.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line treatment options for metastatic urothelial carcinoma: balancing efficacy, safety, and individual values and preferences through shared decision making.","authors":"Yoshiyuki Nagumo, Bryan J Mathis, Hiroyuki Nishiyama","doi":"10.1007/s10147-025-02873-4","DOIUrl":"https://doi.org/10.1007/s10147-025-02873-4","url":null,"abstract":"<p><p>Metastatic urothelial carcinoma (mUC) remains a disease with poor prognosis. While conventional platinum-based chemotherapy has long served as the standard first-line treatment, its survival benefit is limited, particularly in cisplatin-ineligible patients. The introduction of immune checkpoint inhibitors and antibody-drug conjugates as part of sequential treatment has improved outcomes, with pembrolizumab, avelumab, and enfortumab vedotin (EV) providing survival benefit in later lines. In 2024, the EV plus pembrolizumab (EV + P) regimen demonstrated a striking improvement in overall survival compared to chemotherapy followed by maintenance avelumab, representing a paradigm shift toward maximizing efficacy at the initial treatment stage. However, the safety profile of EV + P has specific safety concerns, including skin reactions, peripheral neuropathy, and immune-related adverse events. To fully realize the survival benefits of this combination, careful management and continued treatment are essential, especially in older adults, patients with poor general condition, or those with limited family support. In real-world practice, treatment decisions should be based not only on efficacy but also on safety, patient values and preferences, general condition, and social background. Therefore, shared decision making (SDM) has become increasingly important as a practical approach to adjust first-line treatment strategies. This review summarizes the developing landscape of first-line treatment options for mUC, evaluates the clinical and real-world implications of EV + P, and highlights the importance of SDM in balancing efficacy, safety, and personal values in routine clinical care.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relative survival among cancer survivors enrolled in private cancer insurance in Japan, using the internal insurance-enrolled population as the reference.","authors":"Makoto Hiraoka, Hayaka Uekusa, Akira Okada, Reiko Inoue, Kayo Ikeda-Kurakawa, Yusuke Otsuka, Daisuke Namiki, Ryuichi Yamamoto, Toshimasa Yamauchi, Masaomi Nangaku, Kazuhiko Ohe, Satoko Yamaguchi, Takashi Kadowaki","doi":"10.1007/s10147-025-02871-6","DOIUrl":"https://doi.org/10.1007/s10147-025-02871-6","url":null,"abstract":"<p><strong>Background: </strong>Limited data are available on relative survival (RS) among cancer survivors enrolled in private cancer insurance in Japan. Additionally, the incidence of second primary cancers or recurrences, as applicable, after a certain period remains unclear.</p><p><strong>Methods: </strong>We analyzed 8,846 cancer survivors, including carcinoma in situ, aged 15-79 years, enrolled in private cancer insurance between April 2005 and September 2021, and diagnosed before April 2022. Using the entire insurance-enrolled population as the reference, we estimated sex- and age group-specific RS, conditional RS (CRS), and age-standardized RS (ASR) by cancer type. The cumulative incidence of second primary cancers or recurrences, as applicable, was calculated among cancer-free 3-, 4-, and 5-year survivors.</p><p><strong>Results: </strong>Median ages at first diagnosis were 61.5 years for males and 55.0 years for females. Over median follow-up of 3.40 years, 1,772 deaths (45.4 per 1,000 person-years) occurred. The 5-year RS declined with age: 81.8% for males and 94.8% for females aged 15-39, but 68.5% and 71.8% for those aged 70-79. The 5-year CRS increased with time since diagnosis, exceeding 90% among 5-year survivors in all groups except males aged 70-79. Liver cancer survivors had the highest incidence of second primary cancers or recurrences, predominantly due to recurrences, even after 5 cancer-free years.</p><p><strong>Conclusion: </strong>We estimated sex- and age group-specific RS, CRS, and ASR by cancer type, and the incidence of second primary cancers or recurrences, using a database of private cancer insurance policyholders, though the findings may not be generalizable to the national population.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive-behavioral and mindfulness-based therapies for mental health and quality of life of breast cancer patients: a meta-analysis of randomized controlled trials.","authors":"Ruiyi Su, Ruixiang Wang, Zhuyi Li, Yunyun Wang, Xiaoye Zhao, Yihan Sun, Jingwei Ni, Yichun Zhu, Jie Luan, Guangyu Tian, Tian Tian","doi":"10.1007/s10147-025-02875-2","DOIUrl":"https://doi.org/10.1007/s10147-025-02875-2","url":null,"abstract":"<p><strong>Background: </strong>To evaluate the effects of cognitive-behavioral therapy (CBT) and mindfulness-based therapy (MBT), individually and in combination, on alleviating anxiety and depression, and improving quality of life (QoL) in breast cancer patients.</p><p><strong>Methods: </strong>We searched PubMed and EMBASE for articles published up to April 6, 2025, using the keywords \"randomized controlled trials (RCTs)\", \"cognitive-behavioral therapy\", \"mindfulness-based therapy\", and \"breast cancer\". Pooled effects were expressed as standardized mean differences (SMDs) and 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Fifty-one RCTs were included. Compared with controls (usual care, wait-list control, etc.), CBT and MBT (analyzed separately or in combination) demonstrated significant benefits. The SMDs (95% CIs) were as follows: anxiety [CBT ( - 0.33,  - 0.52 to  - 0.14); MBT ( - 0.80,  - 1.16 to  - 0.45); combined ( - 0.55,  - 0.74 to  - 0.37)], depression [CBT ( - 0.31,  - 0.49 to  - 0.14); MBT ( - 0.80,  - 1.12 to  - 0.48); combined ( - 0.55,  - 0.73 to  - 0.37)] and QoL [CBT (0.38, 0.15 to 0.62); MBT (0.33, 0.11 to 0.55); combined (0.37, 0.20 to 0.53)]. MBT showed significantly greater efficacy than CBT for anxiety (p = 0.020) and depression (p = 0.009). Pooled effects of CBT and MBT were stronger for group-based and longer duration interventions (all outcomes), with effects on depression and QoL being especially strong in Asians. Face-to-face CBT outperformed internet-delivered CBT across all outcomes.</p><p><strong>Conclusion: </strong>CBT and MBT, individually and combined, are effective for anxiety, depression, and QoL in breast cancer patients, with MBT demonstrating superior efficacy for anxiety and depression. The selection of psychological treatments for breast cancer patients should consider intervention method, ethnicity, intervention duration, and delivery format.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan.","authors":"Yoshikazu Nagase, Satoshi Nakagawa, Mariya Kobayashi, Hiroki Kurahashi, Hiromi Ogimoto, Ayaka Tanaka, Tomoko Tsujie, Mayu Shiomi, Akiko Otake, Kanji Masuhara, Kenichi Yoshikawa, Fusanori Yotsumoto, Tomoko Kurita, Kiyoshi Yoshino, Emi Yoshioka, Tomomi Egawa-Takata, Wataru Kudaka, Masayuki Sekine, Hikari Unno, Masahiko Takemura, Saki Aso, Kentaro Kai, Eiji Kobayashi, Takeshi Yokoi, Masashi Akada, Reisa Kakubari, Tsuyoshi Hisa, Shinya Matsuzaki, Yutaka Ueda","doi":"10.1007/s10147-025-02842-x","DOIUrl":"https://doi.org/10.1007/s10147-025-02842-x","url":null,"abstract":"<p><strong>Background: </strong>Lenvatinib plus pembrolizumab (LP) therapy has emerged as an effective treatment for patients with advanced or recurrent endometrial cancer. However, limited data are available regarding its outcomes in real-world settings. This study aimed to identify prognostic factors associated with the efficacy of LP therapy.</p><p><strong>Methods: </strong>This multicenter observational study was conducted across 15 institutions in Japan and examined patients with endometrial cancer, including uterine carcinosarcoma, who experienced disease progression after receiving at least one platinum-based chemotherapy, including adjuvant treatment, and subsequently received LP therapy. The prognostic factors for progression-free survival were assessed using a multivariate Cox proportional hazards model.</p><p><strong>Results: </strong>A total of 105 patients met the inclusion criteria. Improved progression-free survival was independently associated with performance status of 0 (adjusted hazard ratio [aHR] 0.42, 95% confidence interval [CI] 0.23-0.75), platinum-free interval (PFI) of ≥ 6 months (aHR 0.46, 95% CI 0.28-0.78), histology of grade 1-2 endometrioid carcinoma (aHR 0.52, 95% CI 0.30-0.91), and relative dose intensity during the initial 8 weeks (8w-RDI) of lenvatinib of ≥ 50% (aHR 0.53, 95% CI 0.31-0.91). Patients with PFI of ≥ 6 months also demonstrated improved overall survival (HR 0.44, 95% CI 0.25-0.76) and objective response rate (44.0% versus 20.0%, P = 0.011) compared with those with PFI of < 6 months. Additionally, 8w-RDI of lenvatinib ≥ 50% was associated with improved overall survival (HR 0.53, 95% CI 0.30-0.92) compared to those with < 50%.</p><p><strong>Conclusions: </strong>This study identified several novel prognostic factors for LP therapy. Among them, PFI may inform treatment selection for recurrent endometrial cancer following chemotherapy.</p><p><strong>Clinical trial registration: </strong>University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) 000049997.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}